Back to Browse Journals » Clinical Ophthalmology » Volume 1 » Issue 4

Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

Authors Cleber A Trujillo, Arthur A Nery, Janaí­na M Alves, Antonio H Martins, Henning Ulrich

Published Date January 2007 Volume 2007:1(4) Pages 393—402

DOI http://dx.doi.org/

Published 10 January 2007

Cleber A Trujillo1, Arthur A Nery1, Janaína M Alves2, Antonio H Martins1, Henning Ulrich1

1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil; 2Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil

Abstract: Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects.

Keyword: anti-VEGF aptamer, pegaptanib, age-related macular degeneration

Download Article [PDF] 

Readers of this article also read:

Differentiation between chalazion and sebaceous carcinoma by noninvasive meibography

Nemoto Y, Arita R, Mizota A, Sasajima Y

Clinical Ophthalmology 2014, 8:1869-1875

Published Date: 18 September 2014

Adiponectin concentration in the orbital fat of patients with Graves' ophthalmopathy

Soiberman U, Levy R, Leibovitch I

Clinical Ophthalmology 2013, 7:1723-1726

Published Date: 26 August 2013

Cubic phase nanoparticles for sustained release of ibuprofen formulation characterization and enhanced bioavailability study

Dian L, Yang Z, Li F, Wang Z, Pan X, Peng X, Huang X, Guo Z, Quan G, Shi X, Chen B, Li G, Wu C

International Journal of Nanomedicine 2013, 8:845-854

Published Date: 26 February 2013

Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations

Bonelli P, Tuccillo FM, Federico A, Napolitano M, Borrelli A, Melisi D, Rimoli MG, Palaia R, Arra C, Carinci F

International Journal of Nanomedicine 2012, 7:5683-5691

Published Date: 9 November 2012

Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α

Manoharan Y, Ji Q, Yamazaki T, Chinnathambi S, Chen S, Ganesan S, Hill JP, Ariga K, Hanagata N

International Journal of Nanomedicine 2012, 7:3625-3635

Published Date: 16 July 2012

Facile hydrothermal preparation of titanium dioxide decorated reduced graphene oxide nanocomposite

Chang BYS, Huang NM, An'amt MN, Marlinda AR, Norazriena Y, Muhamad MR, Harrison I, Lim HN, Chia CH

International Journal of Nanomedicine 2012, 7:3379-3387

Published Date: 5 July 2012

Paraneoplastic retinopathy associated with retroperitoneal liposarcoma

Mineo Kondo, Kumiko Mokuno, Ai Uemura, et al

Clinical Ophthalmology 2010, 4:243-245

Published Date: 30 March 2010

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009

Clinical efficacy and safety of statins in managing cardiovascular risk

Navin K Kapur, Kiran Musunuru

Vascular Health and Risk Management 2008, 4:341-353

Published Date: 6 May 2008